Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.68 |
| ▸ | AOC3 | Q16853 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14769096 | 1.00 | BCAT2 (0.68) | BCAT2AOC3KDM4EL3MBTL1NPC1 | |
| SCHEMBL2580473 | 0.81 | BCAT2 (0.50) | BCAT2AOC3KDM4EL3MBTL1NPC1 | |
| SCHEMBL21556906 | 0.81 | BCAT2 (0.46) | BCAT2AOC3KDM4EL3MBTL1NPC1 | |
| SCHEMBL18741225 | 0.81 | AOC3 (0.46) | BCAT2AOC3KDM4EL3MBTL1NPC1 | |
| SCHEMBL18401314 | 0.81 | BCAT2 (0.46) | BCAT2AOC3KDM4EL3MBTL1NPC1 | |
| SCHEMBL13840697 | 0.81 | ALDH1A1 (0.46) | BCAT2AOC3KDM4ENPC1RAB9A | |
| SCHEMBL14769097 | 0.81 | HIF1A (0.61) | BCAT2AOC3KDM4ERAB9ALMNA | |
| SCHEMBL20852549 | 0.81 | HIF1A (0.61) | BCAT2AOC3KDM4ERAB9ALMNA | |
| SCHEMBL4530594 | 0.81 | BCAT2 (0.68) | BCAT2AOC3KDM4EL3MBTL1NPC1 | |
| SCHEMBL21408380 | 0.81 | GBA1 (0.46) | BCAT2AOC3KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060127309-A1 | Imaging agents | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2006-06-15 | — | — | US | claimed |
| EP-3567029-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | Lantheus Medical Imaging, Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| US-10259781-B2 | Imaging agents | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170190658-A1 | IMAGING AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-07-06 | — | — | US | disclosed |
| US-20150246142-A1 | IMAGING AGENTS | UNIV MICHIGAN (US) | 2015-09-03 | — | — | US | disclosed |
| US-7534418-B2 | Imaging agents | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-05-19 | — | — | US | disclosed |
| US-20060127309-A1 | Imaging agents | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246142-A1 | IMAGING AGENTS | SLC18A1, VHL, GDI1 | BCAT2 2984/4885AOC3 1654/4885KDM4E 1520/4885 |
| US-20060127309-A1 | Imaging agents | MPI, NPC1, NPC1L1 | BCAT2 3648/4885AOC3 3108/4885KDM4E 4387/4885 |
| US-10259781-B2 | Imaging agents | SLC18A1, VHL, GDI1 | BCAT2 2984/4885AOC3 1654/4885KDM4E 1520/4885 |
| US-20170190658-A1 | IMAGING AGENTS | SLC18A1, VHL, GDI1 | BCAT2 2984/4885AOC3 1654/4885KDM4E 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.